DMD results, page-14

They are not only different drugs so you can't simply or logically substitute ATL1102 for Edasalonexent in the phase 2 Catabasis press release.

As @itsagas has pointed out the trials involved:

• two different populations;
• two drugs with different targeted biomarkers;
• different mechanisms of operation;
• different endpoints;
• different natural history stage implications.

The things in common are the open label nature of Phase 2, the disease being targeted and the use of the word inflammation.

The board, regulators and investigators will know better than me whether placebo is necessary and I can understand the concerns being raised about the risks of investing in biotechs going into phase 3.